Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02109016
Title A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Clovis Oncology, Inc.
Indications

lung non-small cell carcinoma

Therapies

Lucitanib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU

Additional content available in CKB BOOST